LB Pharmaceuticals (LBRX) vs Latigo Biotherapeutics (LTGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LB Pharmaceuticals is the larger company by market cap ($1.19 billion vs $1.06 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | LTGO |
|---|---|---|
| Share price | $36.95 | $15.99 |
| Market cap | $1.19B | $1.06B |
| 1-day change | +6.75% | +8.11% |
| YTD return | +55.48% | — |
| 1-year return | +130.12% | — |
| P/E ratio (TTM) | 369.45 | — |
| EPS (TTM) | $0.10 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.16 | $25.93 |
| 52-week low | $14.32 | $14.60 |
| Distance from 52-week high | -26.35% | -38.33% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +55.10% | +226.77% |
| Average volume | 344.34K | 391.26K |
| Shares outstanding | 32.26M | 66.30M |
| Employees | 49 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
LBRX vs LTGO FAQ
Which is bigger, LB Pharmaceuticals or Latigo Biotherapeutics?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.19B compared with $1.06B for Latigo Biotherapeutics (LTGO).
Are LB Pharmaceuticals and Latigo Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.